Orthopedic Regenerative Surgical Products Market Size, Share & Trends Analysis Report Product Outlook (Allografts, Synthetic, Cell-based, Viscosupplements), Application Outlook (Orthopedic Pain Management, Trauma Repair, Cartilage & tendon repair, Joint reconstruction, Others), End-Use Outlook (Hospitals, Ambulatory Surgical Centers, Others) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Market Overview

The global orthopedic regenerative surgical products market size was valued at USD 3.98 billion in 2021 and is projected to reach USD 6.01 billion by 2030, registering a CAGR of 4.68% from 2022 to 2030.

Traditional orthopaedic therapies and specialised regenerative medicine procedures offered at the SMaRT Institute are combined in regenerative orthopaedics. Before performing invasive surgery, the emphasis is on supporting natural healing. Modern technology is used in regenerative orthopaedics to promote and hasten to heal. Depending on your age, state of health, and degree of ailment. You can recover from sports injuries or post-surgery rehabilitation with the aid of these procedures. In patients with arthritis and other chronic conditions, regenerative orthopaedics can also aid in restoring joint function.

The improvement of short-term patient morbidity and initial, mid-term, and long-term patient outcomes was made possible over time by optimising implants and developing novel minimally invasive arthroscopic technical skills. In the pursuit of continuous improvement, biological and regenerative adjuncts have developed to speed up the healing process. Fundamental advances in basic science have significantly revealed the workings of critical regenerative and healing pathways. The availability of a broad range of primary and supplemental regenerative therapies is rising, including preparations made from bone marrow, growth factors, and stem cells. In this new era of biologically active material application, supportive therapies that are both effective during the index procedure and in the The postoperative period is revolutionising clinical practice. In an effort to increase success and outcome, many aspects of orthopaedic surgery are currently being enhanced by regenerative therapies.

Market Dynamics

Global orthopedic regenerative surgical products market driver

The rising prevalence in the geriatric population

The leading contributor to disability in the elderly and a significant market driver is orthopaedic conditions like osteoarthritis. The prevalence of knee osteoarthritis was found to be 16% worldwide, according to research that the National Natural funded Science Foundation Council of China and published in The Lancet. The prevalence, which was higher in people over 40, was predicted to be 22.9%, or 645.1 million people, in 2020. Due to sedentary lifestyles, obesity, and an ageing population, the incidence is predicted to rise throughout the forecast period, driving the market for orthopaedic regenerative surgical products.

Technological advancements fueled by increasing R&D

Orthopaedic regenerative surgical products are expected to benefit from technological advancements brought on by rising R&D studies and the use of cutting-edge technologies like stem cells, viscosupplements, and Platelet Rich Plasma (PRP) therapies. 70 per cent of respondents to 2020 a survey that was reported in the International Journal of Complementary and Alternative medicine had favourable opinions of regenerative medicine therapies for treating musculoskeletal issues. Participants who had firsthand experience with regenerative medicine, therapies received a more favourable response. The use of PRP and stem cell-based therapies is at the forefront of research in regenerative medicine for conditions like osteoarthritis, trauma healing, and the repair of damaged tissues.

Global orthopedic regenerative surgical products market restraint

Poor reimbursement scenarios and stringent regulatory scenarios

The Centers for Medicare and Medicaid Services (CMS) choose which procedures and innovations are worth paying for and develop payment plans. CMS recently reduced its reimbursement rates, potentially costing hospitals and surgical facilities billions of dollars. A new value-based payment system called the Comprehensive Care for Joint Replacement model was established by CMS in 2016. This guides how CMS pays outpatient orthopaedic surgery costs to nursing homes, hospitals, and other facilities. Hospitals and surgical centres risk losing billions due to the change from the previous reimbursement model.

Regional Analysis

According to the region, the market is segmented into North America; Europe; Asia Pacific; Latin America, and Middle East & Africa.

North America dominated the orthopaedic regenerative surgical products market America also controlled the largest revenue share. This is explained by the existence of essential players, an ageing population, and highly developed medical facilities in the United States and Canada. Due to the high prevalence of chronic orthopaedic diseases and the rising elderly population, Europe held the second-largest share. The risk of developing orthopaedic disorders rises. As a result, increasing the demand for orthopaedic regenerative surgical products. The orthopaedic regenerative surgical products market in the Asia Pacific is anticipated to experience the fastest CAGR during the forecast period. The growing prevalence of orthopaedic disorders like osteoarthritis and the expansion of key players into new regions are to blame for this.

Segmental Analysis

The global orthopedic regenerative surgical products market is segmented by product, application, end-use and region. Based on product, the market is divided into allografts, Synthetic, Cell-based and Viscosupplements. The market for orthopaedic regenerative surgical products was dominated by the viscosupplements segment, which also had the highest revenue share. The increased prevalence of osteoarthritis and knee pain is responsible for this growth. The orthopaedic regenerative surgical products market is driven by ageing, obesity, excessive exercise, external injury, and genetic predisposition that further contribute to knee osteoarthritis. Over the forecast period, the allografts segment is anticipated to experience the fastest CAGR. This is due to the growing use of allografts in orthopaedic surgeries, such as fresh-frozen meniscal allografts, osteochondral allografts, and cartilage purchased off the shelf, and soft tissue allografts.

By application, the market is segmented into Orthopedic Pain Management, Trauma Repair, Cartilage & tendon repair, Joint reconstruction and Others. The joint reconstruction segment led the market for orthopaedic regenerative surgical products, which also accounted for the largest revenue share. The major drivers of this share are rising surgical procedures, regenerative joint reconstruction adoption, and technological advancements. For example, Amniox Medical, Inc. provides surgical allografts from its Clarix line for use in orthopaedic surgery for a variety of procedures like trauma and reconstruction, arthroplasty, and soft-tissue repair.

Based on end-use, the market is categorized into Hospitals, Ambulatory Surgical Centers and Others. The hospital sector dominated the market for orthopaedic regenerative surgical products, which also contributed the largest revenue share. Hospitals are a crucial component of the healthcare sector and the primary source of revenue for the entire industry, stimulating research and innovation. A higher percentage of orthopaedic procedures are carried out in hospital settings, which is one of the factors causing the segment's large share.

Recent Developments

• In May 2022: Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the X-TwistTM Knotless Fixation System. The X-Twist Knotless Fixation system is a platform of suture anchors designed to be mechanically strong1, easy to use, and support healing for key repairs such as rotator cuff repair.
• In March 2022: Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, announced the release of WalkAI™, a dynamic artificial intelligence (AI) model that identifies patients who are predicted to have a lower gait speed outcome at 90 days after hip or knee surgery. WalkAI, the company's first AI-based solution, adds powerful predictive analytic capabilities to ZBEdge™, a suite of integrated smart, digital and robotic technologies purposefully engineered to deliver transformative datapowered clinical insights with the goal of improving patient outcomes.